This study identifies ACTL6A as a key regulator of aerobic glycolysis and hypoxic cell growth in HNSCC, defines a novel association between ACTL6A expression and AP-1 signaling, and establishes a synthetic lethality strategy to drive tumor killing in a treatment resistant HNSCC cell line. The gene discussed is FOS; the disease is head and neck squamous cell carcinoma.